Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners

January 23, 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute’s Advisory Committee, Baylor University Medical Center, discusses the emerging technology of liquid biopsies and the clinical success associated with them.

January 23, 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the unmet need for symptom control in patients with gastrointestinal cancers.

December 18, 2017

Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.

November 22, 2017

Carlos Becerra, MD, discusses the current management and emerging therapies for patients with pancreatic cancer.

November 17, 2017

Carlos Becerra, MD, physician, Texas Oncology, discusses emerging treatments for patients with pancreatic cancer.

March 28, 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, and 2016 Giant of Cancer Care in Community Outreach, discusses the future role of chemotherapy in the treatment landscape of triple-negative breast cancer.

February 08, 2017

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses hair loss prevention treatment for patients with breast cancer.

August 13, 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.

August 05, 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses what recent research has shown regarding phosphoprotein assays in treatment decision-making for patients with breast cancer.

June 29, 2015

One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.

June 04, 2015

Baylor Research Institute (BRI) at Dallas and the Translational Genomics Research Institute in Phoenix, AZ, today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

April 29, 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.

April 27, 2015

Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.

April 24, 2015

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

April 13, 2015

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

April 08, 2015

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

April 07, 2015

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

March 26, 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.

July 18, 2014

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

August 19, 2013

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.